Investment Considerations Calidi’s unique OV platforms are engineered to protect and amplify the virus – increasing efficacy and enhancing tumor targeting and patient safety. Calidi’s lead programs, CLD-400, CLD-201, and CLD-101, are advancing through key development stages. The company targets a $13-15 billion U.S. market across multiple high-need cancer types, including GBM, TNBC, soft tissue … Continue reading “Calidi Biotherapeutics Inc. (NYSE American: CLDI)”
Symbol | Release | Time |
---|---|---|
{{ release.qmtopics.qmsymbol[0].symbol }} | {{ release.headline }} | {{ release.datetime | amDateFormat:'hh:mm A'}} |